All In Biotech

Free tool

FAERS Monitor: Aldactazide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 012616 or its brand name (Aldactazide, Hydrochlorothiazide, Spironolactone). Reports on generic versions are filed under their own applications.

Reports

777

Serious

421

54% of reports

Hospitalization

271

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea99
  • fatigue75
  • headache73
  • nausea72
  • diarrhoea70
  • dizziness55
  • cough51
  • pain45
  • infusion site pain41
  • off label use40
  • malaise37
  • pneumonia36
  • oedema peripheral35
  • pain in extremity35
  • fall34

Reports by year received

View as table
YearReports
20043
20051
20061
20082
20091
20101
201111
201223
20137
201413
201525
201617
201714
201835
201928
202049
202141
202245
202390
2024150
2025144
202676

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion site painSignal4186.464.13,367
oedema peripheralSignal357.85.6201
coughSignal514.93.8158
dyspnoeaSignal994.73.9296
pain in extremitySignal353.22.352
headacheSignal733.22.5108
pneumoniaSignal363.02.247
dizzinessSignal553.02.372
diarrhoeaSignal702.92.390
fallSignal342.82.037
fatigueSignal752.62.176
nauseaSignal722.52.063
malaiseSignal372.31.726
pain452.01.522
off label use401.20.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.